<DOC>
	<DOCNO>NCT00560170</DOCNO>
	<brief_summary>Multiple clinical trial , use 3-hydroxy-3-methylglutaryl coenzyme A ( HMG CoA ) reductase inhibitor ( statin ) , show benefit primary secondary prevention atherosclerotic complication . However , till , incomplete understand mechanisms biologic effect statins beyond LDL cholesterol ( LDL-C ) reduction , accumulate evidence Rho-GTP/Rho-Kinase pathway ( Rho/Rho-K ) play important role may strategic therapeutic target cardiovascular disease . With similar LDL-C reduction ability , availability Ezetimibe offer potential begin address question whether benefit confer statin may accrue independently effect LDL-C lowering . A good understanding role Rho/Rho-kinase signal pathway pathogenesis atherosclerosis human essential . Inhibition Rho/Rho-kinase statin may explain biological beneficial effect statins observed clinical trial . This study aim translate patient important experimental discovery regard initiation inflammation atherosclerosis attempt improve upon present treatment cardiovascular disease .</brief_summary>
	<brief_title>Vascular Effects Ezetimibe/Simvastatin Simvastatin Atherosclerosis</brief_title>
	<detailed_description>Study Design : A single-blind control trial two arm conduct National Chen-Kung University Hospital ( NCKUH ) . We screen subject stable atherosclerosis complete enrollment 40 subject study ( see inclusion exclusion criterion section ) . A central pharmacist NCKUH randomize patient 40mg Simvastatin ( n=20 ) 10mg/10mg Ezetimibe/Simvastatin ( n=20 ) 28 day . If patient already statin two-week washout period 2 week prior trial initiation . Primary Outcomes measurement : The primary outcome mean change Rho-kinase expression activity leukocytes response 40mg Simvastatin ( n=20 ) 10mg/10mg Ezetimibe/Simvastatin ( n=20 ) 28 day . Secondary Outcomes measurement : The secondary outcome correlation mean change Rho-kinase expression activity leukocytes vascular tissue mean change LDL-C , hsCRP , BAFMD , well relation clinical characteristic . Subjects : Participants recruit ambulatory clinic NCKUH Clinic . Inclusion Criteria : 1 . Male female subject age 40 80 year 2 . Documented stable atherosclerosis angiography vascular ultrasound ( 20 % luminal narrowing ) , peripheral arterial disease type 2 diabetes mellitus ( coronary heart disease ( CHD ) risk equivalent - Adult Treatment Program ( ATP ) -III guideline ) 3 . LDL-cholesterol &gt; 100mg/dL ( indication treat statin ) 4 . Written inform consent 5 . Primary care physician authorization letter participate study . Exclusion criterion : 1 . Inability give consent 2 . Pre-menopausal woman 3 . Current use antibiotic , anti-inflammatory immunosuppressant drug 4 . History LFT &gt; 2 time upper normal limit 5 . History myopathy / myositis CPK &gt; 10 time upper normal limit 6 . CPK normal limit study onset 7 . Any evidence inflammatory , infectious neoplastic disease 8 . History CABG , PCI acute ischemic syndrome precede 3 month .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Male female subject age 40 80 year 2 . Documented stable atherosclerosis angiography vascular ultrasound ( 20 % luminal narrowing ) , peripheral arterial disease type 2 diabetes mellitus ( coronary heart disease ( CHD ) risk equivalent Adult Treatment Program ( ATP ) III guideline ) 3 . LDLcholesterol &gt; 100mg/dL ( indication treat statin ) 4 . Written inform consent 5 . Primary care physician authorization letter participate study . Exclusion criterion : 1 . Inability give consent 2 . Premenopausal woman 3 . Current use antibiotic , antiinflammatory immunosuppressant drug 4 . History LFT &gt; 2 time upper normal limit 5 . History myopathy / myositis CPK &gt; 10 time upper normal limit 6 . CPK normal limit study onset 7 . Any evidence inflammatory , infectious neoplastic disease 8 . History CABG , PCI acute ischemic syndrome precede 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>HMG-CoA Reductase Inhibitors</keyword>
	<keyword>endothelial function</keyword>
	<keyword>HMG-CoA Reductase Inhibitors vascular protection</keyword>
</DOC>